A Phase 2 interventional study of 10mg atorvastatin and 80mg atorvastatin in Dyslipidaemias and Dyslipidemias, sponsored by GlaxoSmithKline. Completed at 21 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-16.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.
Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 16th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 2, and was the 24th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 165 across the 47 interventional studies. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 47 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 8 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing atorvastatin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
This compound has been studied in healthy subjects and subjects with type II diabetes and is now being studied in subjects with dyslipidemia. Because many patients with dyslipidemia are on statins, it is important to study how GSK1292263 behaves when taken with a potent statin, atorvastatin. The cholesterol lowering drug, ezetimibe, is included for comparison.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject is eligible to participate if she is of:
Exclusion Criteria:
A medical history of the following:
Note: Subjects may be enrolled in the study if they have had a cholecystectomy three or more months before the time of screening and are stable and asymptomatic.
Heart Rate \< 50 and >100bpm PR Interval \<120 and > 220ms QRS duration \< 70 and >120ms (Bazett) > 450ms Or, has rhythm abnormalities identified during 24-hour screening Holter assessment. Subjects with left bundle branch block are excluded from the study. Subjects with partial right bundle branch block may be considered for inclusion following consultation with the GlaxoSmithKline (GSK) Medical Monitor. Subjects with Wolf-Parkinson-White (WPW) syndrome are excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects on stable 40mg atorvastatin \> 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
Drug: 80mg atorvastatin
Dosing for 14 days
Drug: 800mg GSK1292263
Washout for 4 weeks
Other: Washout
Dosing for 4 weeks
Drug: 10mg atorvastatin
Dosing for 4 weeks
Drug: 80mg atorvastatin
Dosing for 14 days
Drug: 10mg atorvastatin
Dosing for 14 days
Drug: 300mg GSK1292263
Dosing for 14 days
Drug: 10mg atorvastatin · Drug: 800mg GSK1292263
Dosing for 14 days
Drug: 10mg atorvastatin · Drug: 10mg ezetimibe
Dosing for 14 days
Drug: 100mg GSK1292263
Dosing for 14 days
Drug: 300mg GSK1292263
Dosing for 14 days
Drug: 800mg GSK1292263
Dosing for 14 days
Drug: GSK1292263 Placebo
Dosing for 14 days
Drug: 80mg atorvastatin
Dosing for 14 days
Drug: GSK1292263 Placebo
Dosing for 14 days
Drug: 10mg atorvastatin
10mg
Also known as: Lipitor
80mg
Also known as: Lipitor
Placebo
100mg
300mg
800mg
10mg
Also known as: Zetia
No interventions - washout period
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
Time frame: Up to Day 26
Number of Participants With Any AEs and SAEs- Part B (Washout)
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
Time frame: Up to Day 28
Number of Participants With Any AEs and SAEs- Part B (Run-in)
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
Time frame: Up to Day 28
Number of Participants With Any AEs and SAEs- Part B (Pooled Treatment Arm)
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
Time frame: Up to Day 26
Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A
Single ECGs were taken after admission on Day -1 and at Follow-up (up to Day 26). On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No value found to be abnormal clinically significant in Part A of the study.
Time frame: Up to Day 26
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Washout)
ECGs were taken at Screening, and on Day1 and Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings.
Time frame: Up to Day 28
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)
ECGs were taken on Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No data found to be abnormal clinically significant in run-in phase.
Time frame: Day 28
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)
Single ECGs were taken after admission on Day -2, and pre-breakfast on Days -1, 4, 10, and at Follow-up. On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. The data was found to be abnormal clinically significant in treatment phase.
Time frame: Up to Day 26
Number of Participants With Vital Signs of Potential Clinical Importance (PCI)- Part A
Assessment of vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate was performed after admission on Day -1 and at Follow-up. On Days 1, 7 and 14, they were taken at pre-dose, 1, 3, 6, 8, 14 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
Time frame: Up to Day 26
Number of Participants With Vital Signs of PCI- Part B (Washout)
Assessment of vital signs including SBP, DBP heart rate was performed at Screening, on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
Time frame: Up to day 28
Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Run-in)
Assessment of vital signs including SBP, DBP and heart rate was performed on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
Time frame: Up to day 28
Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Pooled Treatment Arm)
Assessment of vital signs including SBP, DBP and heart rate was performed after admission on Day-2, and pre-breakfast on Days -1, 4, and 10 in a fasting state early in the morning (prior to dosing), and at Follow-up. On Days 1, 7 and 14, they were also be taken at 1, 3, 6, 9, 12 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
Time frame: Up to Day 26
Number of Participants With Abnormal Hematology Value of PCI- Part A
Blood samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Data for only those parameters (Hematocrit, Hemoglobin and Total neutrophils) are presented for which findings are of PCI either high or low.
Time frame: Up to Day 26
Number of Participants With Abnormal Hematology Value of PCI- Part B (Washout)
Blood samples were collected at screening, and on Days 1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (White blood cells \[WBC\], Total neutrophils, Hematocrit and Lymphocytes) are presented for which findings are of PCI either high or low.
Time frame: Up to Day 28
Number of Participants With Abnormal Hematology Value of PCI- Part B (Run-in)
Blood samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Lymphocytes) are presented for which findings are of PCI either high or low.
Time frame: Days 14 and 28
Number of Participants With Abnormal Hematology Value of PCI- Part B (Pooled Treatment Arm)
Blood samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24hrs post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24hrs post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Platelet count, Total neutrophils and Lymphocytes) are presented for which findings are of PCI either high or low.
Time frame: Up to Day 26
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A
Samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). No parameter was found to have any value of PCI.
Time frame: Up to Day 26
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Washout)
Samples were collected at screening, and on Days1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Inorganic phosphorus, Sodium, Alanine aminotransferase \[ALT\], Potassium, Creatinine, Calcium, magnesium, Glucose, Total Bilirubin, Carbon dioxide/bicarbonate \[CO2/HCO3\] and Aspartate aminotransferase \[AST\]) are presented for which findings are of PCI either high or low.
Time frame: Up to Day 28
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (run-in)
Samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Glucose, Magnesium, ALT, AST, Calcium, Inorganic phosphorus and Total bilirubin) are presented for which findings are of PCI either high or low.
Time frame: Days 14 and 28
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Pooled Treatment Arm)
Samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24 hours post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Glucose, Total bilirubin, Albumin, Magnesium, CO2/HCO3, Calcium, ALT, AST, Inorganic phosphorus, Potassium and Sodium) are presented for which findings are of PCI either high or low.
Time frame: Up to Day 26
Maximum Observed Concentration (Cmax) of GSK1292263- Part A
Serial blood samples for the determination of the PK for GSK1292263 on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).
Time frame: On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Cmax of GSK1292263- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).
Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Time of Occurrence of Cmax (Tmax) and Terminal Phase Half-life (t1/2) GSK1292263- Part A
Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).
Time frame: On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A
Serial blood samples for the determination of the PK for GSK1292263 on Days 1 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48h sample on Day 1).
Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Tmax and t1/2 of GSK1292263- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).
Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Tlag of GSK1292263- Part B (Pooled Treatment Arm)
Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.
Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours [AUC(0-24)] of GSK1292263- Part A
Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).
Time frame: On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
AUC(0-24) of GSK1292263- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).
Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Trough Concentration of GSK1292263
Trough samples for GSK1292263 PK (all treatment arms) were planned to be collected early in the morning on Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48h PK sample was collected on Day 16). (pre-dose for Days 13 and 14; trough Day 15 = 24h post last dose; trough Day 16 = 48h post last dose).
Time frame: On Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Cmax of Atorvastatin- Part A
Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Cmax of Atorvastatin- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Tmax of Atorvastatin- Part A
Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Tmax of Atorvastatin- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
AUC (0-24) of Atorvastatin- Part A
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
AUC (0-24) of Atorvastatin- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Trough Concentration of Atorvastatin
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were planned to be collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were planned to be collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were planned to be collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was planned to be collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Percent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
Time frame: Baseline and Day 14
Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
Time frame: Baseline and Day 14
Percent Change From Baseline in Lipid Metabolism: High Density Lipids Cholesterol (HDLc), Low Density Lipids Cholesterol (LDLc), Tryglycerides, Non-HDLc and Total Cholesterol at Day 14 (24 Hours)
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
Time frame: Baseline and Day 14
Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
Time frame: Baseline and Day 14
Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was Day -1 value. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
Time frame: Baseline and Day 14
Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose and on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Trough Concentration of Atorvastatin Metabolite (2-Hydroxyatorvastatin)
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were supposed to collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were supposed to collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were supposed to collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16). However no data was collected.
Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
The study was conducted at 21 centers in the United States during the period 14 September 2010 to 29 June 2011. There were 6 total participants in Part A, then Part B started with total of 281 participants which flowed through the rest of the phases of the trial. Part B had washout phase and run-In phase followed by treatment phase.
| Milestone | Part A | Part B Washout | Part B Run-in | Part B Pooled Treatment Arm |
|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 |
| Completed | 6 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part A | Part B Washout | Part B Run-in | Part B Pooled Treatment Arm |
|---|---|---|---|---|
| Started | 0 | 281 | 0 | 0 |
| Completed | 0 | 136 | 0 | 0 |
| Not completed | 0 | 145 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 14 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 14 | 0 | 0 |
| Withdrew: Reached defined stopping criteria | 0 | 2 | 0 | 0 |
| Withdrew: Did not meet continuation criteria | 0 | 112 | 0 | 0 |
| Milestone | Part A | Part B Washout | Part B Run-in | Part B Pooled Treatment Arm |
|---|---|---|---|---|
| Started | 0 | 0 | 89 | 0 |
| Completed | 0 | 0 | 83 | 0 |
| Not completed | 0 | 0 | 6 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 0 |
| Milestone | Part A | Part B Washout | Part B Run-in | Part B Pooled Treatment Arm |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 130 |
| Completed | 0 | 0 | 0 | 127 |
| Not completed | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
| Participants | 80 mg Atorvastatin + 800 mg GSK1292263 | 800 mg GSK1292263 |
|---|---|---|
| Any AE | 0 | 2 |
| Any SAE | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
| Participants | Pre-treatment | Washout |
|---|---|---|
| Any AE | 14 | 37 |
| Any SAE | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
| Participants | Atorvastatin 10 mg | Atorvastatin 80 mg |
|---|---|---|
| Any AE | 19 | 8 |
| Any SAE | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.
| Participants | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any AE | 6 | 2 | 3 | 3 | 4 | 6 | 4 | 5 | 7 | 8 | 4 |
| Any SAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Single ECGs were taken after admission on Day -1 and at Follow-up (up to Day 26). On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No value found to be abnormal clinically significant in Part A of the study.
| Participants | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A | 0 | 0 |
ECGs were taken at Screening, and on Day1 and Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings.
| Participants | Washout |
|---|---|
| Day 1 | 1 |
| Day 28 | 1 |
ECGs were taken on Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No data found to be abnormal clinically significant in run-in phase.
| Participants | Atorvastatin 10 mg | Atorvastatin 80 mg |
|---|---|---|
| Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in) | 0 | 0 |
Single ECGs were taken after admission on Day -2, and pre-breakfast on Days -1, 4, 10, and at Follow-up. On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. The data was found to be abnormal clinically significant in treatment phase.
| Participants | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Assessment of vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate was performed after admission on Day -1 and at Follow-up. On Days 1, 7 and 14, they were taken at pre-dose, 1, 3, 6, 8, 14 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| DBP, high | 0 | 1 |
| DBP, low | 0 | 0 |
Assessment of vital signs including SBP, DBP heart rate was performed at Screening, on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
| Participants | Washout |
|---|---|
| SBP, high | 4 |
| Heart rate, high | 1 |
Assessment of vital signs including SBP, DBP and heart rate was performed on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 10 mg | Atorvastatin 80 mg |
|---|---|---|
| SBP, high | 1 | 0 |
| SBP, low | 0 | 0 |
Assessment of vital signs including SBP, DBP and heart rate was performed after admission on Day-2, and pre-breakfast on Days -1, 4, and 10 in a fasting state early in the morning (prior to dosing), and at Follow-up. On Days 1, 7 and 14, they were also be taken at 1, 3, 6, 9, 12 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, high | 0 | 0 | 1 | 3 | 2 | 1 | 2 | 1 | 2 | 0 | 0 |
| DBP, high | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| DBP, low | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Heart rate, high | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Data for only those parameters (Hematocrit, Hemoglobin and Total neutrophils) are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| Hematocrit, high | 2 | 1 |
| Hemoglobin, high | 2 | 0 |
| Total neutrophil, low | 1 | 0 |
Blood samples were collected at screening, and on Days 1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (White blood cells \[WBC\], Total neutrophils, Hematocrit and Lymphocytes) are presented for which findings are of PCI either high or low.
| Participants | Washout |
|---|---|
| WBC, high | 1 |
| WBC, low | 1 |
| Total neutrophil, low | 1 |
| Hematocrit, high | 2 |
| Lymphocytes, low | 2 |
Blood samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Lymphocytes) are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 10 mg | Atorvastatin 80 mg |
|---|---|---|
| Lymphocytes, low | 0 | 1 |
| Lymphocytes, high | 0 | 0 |
Blood samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24hrs post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24hrs post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Platelet count, Total neutrophils and Lymphocytes) are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Platelet count, low | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total neutrophils, low | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lymphocytes, low | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). No parameter was found to have any value of PCI.
| Participants | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A | 0 | 0 |
Samples were collected at screening, and on Days1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Inorganic phosphorus, Sodium, Alanine aminotransferase \[ALT\], Potassium, Creatinine, Calcium, magnesium, Glucose, Total Bilirubin, Carbon dioxide/bicarbonate \[CO2/HCO3\] and Aspartate aminotransferase \[AST\]) are presented for which findings are of PCI either high or low.
| Participants | Washout |
|---|---|
| Inorganic phosphorus, high | 3 |
| Inorganic phosphorus, low | 2 |
| Sodium, high | 1 |
| Sodium, low | 1 |
| ALT, high | 3 |
| Potassium, high | 3 |
| Potassium, low | 1 |
| Creatinine, high | 1 |
| Calcium, high | 2 |
| Magnesium, high | 32 |
| Glucose, high | 4 |
| Glucose, low | 1 |
| Total bilirubin, high | 6 |
| CO2/bicarbonate, low | 1 |
| AST, high | 1 |
Samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Glucose, Magnesium, ALT, AST, Calcium, Inorganic phosphorus and Total bilirubin) are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 10 mg | Atorvastatin 80 mg |
|---|---|---|
| Glucose, high | 1 | 0 |
| Magnesium, high | 5 | 5 |
| ALT, high | 1 | 0 |
| AST, high | 1 | 0 |
| Calcium, high | 0 | 1 |
| Inorganic phosphorus, low | 0 | 1 |
| Total bilirubin, high | 0 | 1 |
Samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24 hours post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Glucose, Total bilirubin, Albumin, Magnesium, CO2/HCO3, Calcium, ALT, AST, Inorganic phosphorus, Potassium and Sodium) are presented for which findings are of PCI either high or low.
| Participants | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, high | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Glucose, low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Total bilirubin, high | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Albumin, low | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Magnesium, high | 0 | 1 | 2 | 1 | 1 | 2 | 3 | 2 | 3 | 2 | 2 |
| CO2/HCO3, high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CO2/HCO3, low | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, high | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Calcium, low | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| ALT, high | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, high | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inorganic phosphorus, high | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Sodium, high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Serial blood samples for the determination of the PK for GSK1292263 on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).
| nanograms per milliliter | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| Day 1 | 976.335 ± 16.6353 | 986.811 ± 46.4825 |
| Day 14 | 1118.344 ± 20.6141 | 948.764 ± 6.5356 |
For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).
| nanograms per milliliter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg |
|---|---|---|---|---|---|---|---|
| Day 1 | 281.321 ± 35.9671 | 475.297 ± 36.5131 | 808.278 ± 20.0646 | 790.315 ± 32.5080 | 263.279 ± 43.0140 | 478.676 ± 21.2079 | 787.922 ± 36.7864 |
| Day 14 | 361.595 ± 25.9981 | 639.687 ± 33.6608 | 886.418 ± 31.3931 | 848.082 ± 25.1892 | 364.936 ± 39.1918 | 590.949 ± 20.7601 | 782.914 ± 81.2992 |
Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).
| hours | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| tmax, Day 1 | 6.000 (4.00 to 8.00) | 5.000 (4.00 to 6.00) |
| tmax, Day 14 | 3.000 (3.00 to 4.00) | 5.067 (4.00 to 6.13) |
| t1/2, Day 1 | 11.185 (8.81 to 11.61) | 16.164 (16.164 to 16.164) |
| t1/2, Day 14 | 20.629 (13.76 to 28.80) | 19.395 (16.54 to 22.25) |
Serial blood samples for the determination of the PK for GSK1292263 on Days 1 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48h sample on Day 1).
| hours | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A | 0.250 (0.00 to 0.50) | 0.000 (0.00 to 0.00) |
For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).
| hours | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg |
|---|---|---|---|---|---|---|---|
| tmax, Day 1 | 3.983 (3.00 to 6.00) | 5.008 (3.98 to 8.00) | 4.000 (4.00 to 8.33) | 4.000 (3.98 to 8.08) | 4.000 (1.50 to 8.00) | 4.000 (2.00 to 8.00) | 3.475 (1.98 to 7.97) |
| tmax, Day 14 | 5.000 (0.83 to 8.00) | 4.000 (2.08 to 4.02) | 4.000 (1.50 to 4.05) | 4.000 (1.50 to 4.00) | 4.000 (3.98 to 6.00) | 3.983 (1.98 to 6.00) | 4.000 (0.43 to 5.98) |
| t1/2, Day 1 | 12.630 (12.63 to 12.63) | 10.270 (6.07 to 10.55) | 10.416 (9.29 to 26.11) | 12.372 (6.72 to 23.08) | 15.305 (12.25 to 21.78) | 14.342 (13.38 to 20.30) | 14.464 (14.464 to 14.464) |
| t1/2, Day 14 | 26.453 (17.02 to 163.25) | 21.569 (15.73 to 37.15) | 21.846 (10.52 to 36.52) | 24.225 (16.86 to 34.21) | 23.893 (17.43 to 43.62) | 25.203 (10.67 to 62.63) | 19.478 (12.40 to 67.78) |
Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.
| hours | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg |
|---|---|---|---|---|---|---|---|
| Tlag of GSK1292263- Part B (Pooled Treatment Arm) | 0.000 (0.00 to 0.50) | 0.000 (0.00 to 0.50) | 0.000 (0.00 to 1.03) | 0.000 (0.00 to 0.50) | 0.000 (0.00 to 1.03) | 0.000 (0.00 to 1.00) | 0.000 (0.00 to 0.50) |
Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).
| nanograms hour per milliliter | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 800 mg |
|---|---|---|
| Day 1 | 12953.89 ± 16.976 | 12032.21 ± NA |
| Day 14 | 13206.52 ± 15.070 | 11890.40 ± 5.730 |
For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).
| nanograms hour per milliliter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 80 mg + GSK1292263 800 mg | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg |
|---|---|---|---|---|---|---|---|
| Day 1 | 4218.02 ± 54.264 | 5373.78 ± 64.021 | 10384.24 ± 15.165 | 9812.21 ± 25.708 | 2753.61 ± 48.535 | 5342.77 ± 18.108 | 8937.99 ± 21.080 |
| Day 14 | 4968.29 ± 24.683 | 7484.67 ± 51.772 | 11224.58 ± 44.087 | 10760.74 ± 22.081 | 4061.78 ± 35.242 | 6737.82 ± 28.082 | 8837.31 ± 79.003 |
Trough samples for GSK1292263 PK (all treatment arms) were planned to be collected early in the morning on Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48h PK sample was collected on Day 16). (pre-dose for Days 13 and 14; trough Day 15 = 24h post last dose; trough Day 16 = 48h post last dose).
No measurements were reported for this outcome.
Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
| nanograms per milliliter | Atorvastatin 80 mg + GSK1292263 800 mg |
|---|---|
| Day -1 | 45.587 ± 130.4168 |
| Day 1 | 25.867 ± 88.8156 |
| Day 14 | 38.443 ± 71.1418 |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| nanograms per milliliter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo |
|---|---|---|---|---|---|---|---|
| Day -1 | 2.045 ± 41.3980 | 2.454 ± 34.6820 | 1.683 ± 54.1388 | 1.816 ± 54.6608 | 2.003 ± 73.2912 | 42.376 ± 113.1276 | 37.058 ± 47.5590 |
| Day 1 | 1.292 ± 26.6345 | 2.195 ± 47.6989 | 1.926 ± 47.0899 | 1.852 ± 57.6472 | 1.872 ± 64.1762 | 31.018 ± 81.5136 | 45.781 ± 38.4790 |
| Day 14 | 1.453 ± 14.5258 | 2.154 ± 69.0856 | 2.139 ± 74.2524 | 1.640 ± 68.6754 | 1.949 ± 56.7747 | 38.419 ± 71.2059 | 41.092 ± 73.0152 |
Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
| hours | Atorvastatin 80 mg + GSK1292263 800 mg |
|---|---|
| Day -1 | 3.000 (0.50 to 4.00) |
| Day 1 | 4.000 (3.00 to 6.00) |
| Day 14 | 2.250 (1.00 to 3.00) |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| hours | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo |
|---|---|---|---|---|---|---|---|
| Day -1 | 2.500 (0.50 to 6.08) | 3.000 (1.50 to 6.00) | 3.983 (0.50 to 5.97) | 3.017 (0.50 to 6.08) | 4.000 (3.00 to 4.00) | 2.508 (0.50 to 6.00) | 1.517 (0.50 to 4.00) |
| Day 1 | 4.992 (3.98 to 6.00) | 6.000 (3.95 to 6.00) | 3.000 (0.50 to 8.33) | 3.992 (1.50 to 6.08) | 4.000 (2.00 to 4.00) | 3.492 (1.03 to 6.03) | 2.000 (0.50 to 4.00) |
| Day 14 | 4.000 (2.83 to 6.00) | 4.000 (3.00 to 6.00) | 3.500 (1.50 to 6.08) | 3.525 (1.50 to 6.00) | 2.000 (1.00 to 3.00) | 2.067 (0.50 to 5.93) | 3.000 (1.00 to 6.05) |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| nanograms hour per milliliter | Atorvastatin 80 mg + GSK1292263 800 mg |
|---|---|
| Day -1 | 219.27 ± 77.893 |
| Day 1 | 199.15 ± 73.974 |
| Day 14 | 187.25 ± 52.566 |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| nanograms hour per milliliter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo |
|---|---|---|---|---|---|---|---|
| Day -1 | 23.16 ± 18.115 | 28.78 ± 26.611 | 19.26 ± 54.767 | 18.77 ± 51.122 | 19.59 ± 47.952 | 188.88 ± 70.744 | 173.62 ± 31.333 |
| Day 1 | 17.84 ± 35.028 | 26.19 ± 30.561 | 20.83 ± 50.427 | 19.33 ± 55.620 | 19.05 ± 48.448 | 174.13 ± 55.829 | 186.73 ± 35.837 |
| Day 14 | 15.58 ± 14.934 | 23.77 ± 38.501 | 20.41 ± 70.602 | 18.60 ± 56.102 | 20.24 ± 41.371 | 174.93 ± 59.199 | 188.31 ± 54.020 |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were planned to be collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were planned to be collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were planned to be collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was planned to be collected on Day 16).
No measurements were reported for this outcome.
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
| Percent change | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apolipoprotein A1, 24 hours | -1.93 ± 27.152 | -8.72 ± 31.791 | 4.17 ± 38.410 | -7.19 ± 27.383 | -3.88 ± 26.818 | -1.00 ± 35.805 | -5.81 ± 47.800 | 3.76 ± 41.281 | 29.90 ± 99.331 | -0.15 ± 39.226 | -0.18 ± 49.478 |
| Apolipoprotein B100, 24 hours | 2.85 ± 31.217 | -17.93 ± 19.839 | -22.22 ± 20.393 | -5.03 ± 19.932 | -15.49 ± 13.681 | -27.08 ± 14.132 | 4.25 ± 27.890 | -10.21 ± 22.072 | -7.62 ± 23.573 | -10.95 ± 23.811 | -2.39 ± 15.932 |
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
| Perecent change | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours) | -21.97 ± 16.373 | -3.92 ± 29.382 | -31.41 ± 17.369 | 34.28 ± 141.042 | -12.27 ± 42.191 | -13.19 ± 19.202 | -13.41 ± 30.613 | 1.35 ± 46.155 | -21.98 ± 37.910 | -33.75 ± 16.915 | -1.58 ± 36.044 |
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
| Percent change | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HDLc | 7.50 ± 13.639 | 14.97 ± 7.700 | 31.09 ± 11.966 | -0.03 ± 14.714 | 6.03 ± 11.850 | 26.22 ± 15.840 | 4.50 ± 10.936 | 9.17 ± 10.277 | 9.76 ± 17.160 | 18.95 ± 12.847 | -1.37 ± 7.140 |
| LDLc | -6.80 ± 14.522 | -10.01 ± 21.231 | -24.09 ± 18.017 | -0.37 ± 19.794 | -24.81 ± 12.317 | -18.63 ± 16.534 | 15.01 ± 59.194 | -10.24 ± 11.438 | -11.86 ± 16.873 | -19.94 ± 10.688 | 0.77 ± 11.347 |
| Triglyceides | -18.67 ± 16.693 | -15.98 ± 24.307 | -32.81 ± 21.249 | 10.70 ± 32.177 | -10.44 ± 21.628 | -21.39 ± 28.190 | 2.27 ± 17.025 | -3.95 ± 23.855 | -30.84 ± 11.753 | -34.66 ± 21.197 | 18.90 ± 18.225 |
| Non-HDLc | -9.53 ± 8.502 | -11.67 ± 18.562 | -26.59 ± 13.742 | 2.08 ± 16.176 | -21.19 ± 11.920 | -21.88 ± 11.157 | -0.94 ± 8.977 | -9.32 ± 13.107 | -17.02 ± 12.376 | -22.62 ± 10.290 | 3.17 ± 9.283 |
| Total cholesterol | -5.17 ± 9.210 | -3.61 ± 12.355 | -10.31 ± 8.912 | 0.89 ± 12.671 | -14.23 ± 9.640 | -5.52 ± 7.721 | 1.09 ± 6.724 | -5.81 ± 10.091 | -12.06 ± 9.650 | -14.05 ± 7.614 | 2.18 ± 7.900 |
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
| Percent change | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours) | -12.25 ± 14.784 | -21.12 ± 20.549 | -41.61 ± 14.248 | 0.94 ± 20.727 | -28.69 ± 11.963 | -34.35 ± 16.047 | 10.84 ± 56.487 | -16.78 ± 15.615 | -17.63 ± 23.327 | -32.01 ± 11.287 | 2.55 ± 12.789 |
Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was Day -1 value. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.
| millimoles per liter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo | GSK1292263 100 mg | GSK1292263 300 mg | GSK1292263 800 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14 | 0.13341 ± -167.395 | 0.30812 ± -360.966 | 0.12845 ± -68.4294 | 0.25228 ± 477.0380 | 0.09060 ± -146.956 | 0.04974 ± -76.1973 | 0.20164 ± -485.961 | 0.30543 ± -159.012 | 0.37442 ± -111.818 | 0.13079 ± -115.210 | 0.28863 ± 93.3050 |
Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
| nanograms per milliliter | Atorvastatin 80 mg + GSK1292263 800 mg |
|---|---|
| Day -1 | 17.521 ± 66.1066 |
| Day 1 | 15.535 ± 48.2576 |
| Day 14 | 21.271 ± 30.4382 |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| nanograms per milliliter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo |
|---|---|---|---|---|---|---|---|
| Day -1 | 1.298 ± 37.3615 | 1.388 ± 42.8163 | 0.947 ± 39.3947 | 0.952 ± 63.1814 | 1.185 ± 119.9675 | 26.106 ± 102.2617 | 21.149 ± 39.5618 |
| Day 1 | 1.073 ± 19.3329 | 1.217 ± 36.0597 | 1.048 ± 33.9165 | 1.028 ± 67.0630 | 1.234 ± 44.7679 | 19.991 ± 71.2442 | 26.400 ± 44.9589 |
| Day 14 | 0.634 ± 12.5545 | 1.152 ± 53.4256 | 1.084 ± 49.9097 | 0.869 ± 62.0112 | 1.349 ± 42.0203 | 22.645 ± 75.7161 | 27.236 ± 68.7891 |
Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
| hours | Atorvastatin 80 mg + GSK1292263 800 mg |
|---|---|
| Day -1 | 3.000 (1.00 to 4.00) |
| Day 1 | 4.000 (4.00 to 6.00) |
| Day 14 | 2.500 (2.00 to 4.00) |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| hours | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo |
|---|---|---|---|---|---|---|---|
| Day -1 | 4.500 (1.00 to 6.08) | 4.000 (3.00 to 8.00) | 5.000 (2.00 to 8.02) | 4.000 (3.00 to 8.00) | 4.000 (4.00 to 6.00) | 3.992 (1.00 to 6.00) | 3.000 (1.00 to 4.00) |
| Day 1 | 6.000 (6.00 to 6.00) | 6.000 (4.00 to 8.00) | 4.000 (2.00 to 14.10) | 4.000 (1.50 to 10.00) | 4.000 (2.00 to 6.00) | 4.000 (1.50 to 6.08) | 3.000 (0.50 to 6.02) |
| Day 14 | 6.000 (2.83 to 8.00) | 4.000 (3.00 to 14.00) | 4.025 (3.00 to 6.08) | 5.000 (1.50 to 14.02) | 6.000 (3.00 to 6.00) | 4.000 (1.50 to 6.00) | 3.983 (1.00 to 6.05) |
Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).
| nanograms hour per milliliter | Atorvastatin 80 mg + GSK1292263 800 mg |
|---|---|
| Day -1 | 119.66 ± 72.635 |
| Day 1 | 127.70 ± 49.098 |
| Day 14 | 139.78 ± 47.491 |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).
| nanograms hour per milliliter | Atorvastatin 10 mg + GSK1292263 100 mg | Atorvastatin 10 mg + GSK1292263 300 mg | Atorvastatin 10 mg + GSK1292263 800 mg | Atorvastatin 10 mg + Placebo | Atorvastatin 10 mg + Ezetimibe 10 mg | Atorvastatin 80 mg + GSK1292263 800 mg | Atorvastatin 80 mg + Placebo |
|---|---|---|---|---|---|---|---|
| Day -1 | 16.72 ± 19.509 | 20.25 ± 47.047 | 14.37 ± 48.598 | 12.38 ± 74.286 | 12.41 ± 53.128 | 163.16 ± 73.666 | 133.96 ± 36.159 |
| Day 1 | 16.02 ± 9.355 | 18.28 ± 40.611 | 14.89 ± 33.541 | 13.60 ± 78.379 | 15.10 ± 26.181 | 146.23 ± 55.353 | 150.41 ± 37.440 |
| Day 14 | 10.07 ± 12.346 | 16.54 ± 37.123 | 13.82 ± 43.131 | 12.03 ± 63.145 | 18.18 ± 36.758 | 144.23 ± 58.954 | 156.41 ± 42.286 |
For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were supposed to collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were supposed to collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were supposed to collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16). However no data was collected.
No measurements were reported for this outcome.
Collected over All AEs and SAEs were collected up to follow-up visit. For Part A- up to Day 26, for Part B (washout)- up to Day 28, for Part B (run-in)- up to day up to day 28 and Part B (treatment)- up to Day 26. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 80 mg Atorvastatin + 800 mg GSK1292263 (Part A) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| 800 mg GSK1292263 (Part A) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Pre-treatment (Part B) | 0/281 (0%) | 0/281 (0%) | 14/281 (5%) |
| Washout (Part B) | 0/281 (0%) | 0/281 (0%) | 37/281 (13.2%) |
| Atorvastatin 10 mg (Part B Run-in) | 0/62 (0%) | 0/62 (0%) | 19/62 (30.6%) |
| Atorvastatin 80 mg (Part B Run-in) | 0/27 (0%) | 0/27 (0%) | 8/27 (29.6%) |
| Atorvastatin 10 mg + GSK1292263 100 mg (Part B Treatment) | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| Atorvastatin 10 mg + GSK1292263 300 mg (Part B Treatment) | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Atorvastatin 10 mg + GSK1292263 800 mg (Part B Treatment) | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Atorvastatin 10 mg + Placebo (Part B Treatment) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Atorvastatin 10 mg + Ezetimibe 10 mg (Part B Treatment) | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Atorvastatin 80 mg + GSK1292263 800 mg (Part B Treatment) | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Atorvastatin 80 mg + Placebo (Part B Treatment) | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| GSK1292263 100 mg (Part B Treatment) | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| GSK1292263 300 mg (Part B Treatment) | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| GSK1292263 800 mg (Part B Treatment) | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Placebo (Part B Treatment) | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Event | 80 mg Atorvastatin + 800 mg GSK1292263 (Part A) | 800 mg GSK1292263 (Part A) | Pre-treatment (Part B) | Washout (Part B) | Atorvastatin 10 mg (Part B Run-in) | Atorvastatin 80 mg (Part B Run-in) | Atorvastatin 10 mg + GSK1292263 100 mg (Part B Treatment) | Atorvastatin 10 mg + GSK1292263 300 mg (Part B Treatment) | Atorvastatin 10 mg + GSK1292263 800 mg (Part B Treatment) | Atorvastatin 10 mg + Placebo (Part B Treatment) | Atorvastatin 10 mg + Ezetimibe 10 mg (Part B Treatment) | Atorvastatin 80 mg + GSK1292263 800 mg (Part B Treatment) | Atorvastatin 80 mg + Placebo (Part B Treatment) | GSK1292263 100 mg (Part B Treatment) | GSK1292263 300 mg (Part B Treatment) | GSK1292263 800 mg (Part B Treatment) | Placebo (Part B Treatment) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/4 | 1/2 | 0/281 | 1/281 | 0/62 | 0/27 | 0/11 | 1/11 | 0/11 | 0/12 | 0/13 | 0/12 | 0/13 | 0/11 | 1/12 | 0/13 | 1/11 |
| VomitingGastrointestinal disorders | 0/4 | 1/2 | 0/281 | 0/281 | 0/62 | 0/27 | 0/11 | 0/11 | 0/11 | 0/12 | 0/13 | 0/12 | 0/13 | 0/11 | 1/12 | 0/13 | 0/11 |
| PhlebitisVascular disorders | 0/4 | 1/2 | 0/281 | 0/281 | 0/62 | 0/27 | 0/11 | 0/11 | 0/11 | 0/12 | 0/13 | 0/12 | 0/13 | 0/11 | 0/12 | 0/13 | 0/11 |
| NauseaGastrointestinal disorders | 0/4 | 0/2 | 0/281 | 2/281 | 3/62 | 0/27 | 0/11 | 0/11 | 1/11 | 0/12 | 0/13 | 0/12 | 0/13 | 0/11 | 4/12 | 0/13 | 0/11 |
| HeadacheNervous system disorders | 0/4 | 0/2 | 0/281 | 7/281 | 7/62 | 1/27 | 3/11 | 1/11 | 1/11 | 0/12 | 2/13 | 2/12 | 3/13 | 2/11 | 1/12 | 2/13 | 2/11 |
| RashSkin and subcutaneous tissue disorders | 0/4 | 0/2 | 0/281 | 0/281 | 0/62 | 0/27 | 2/11 | 0/11 | 0/11 | 0/12 | 0/13 | 0/12 | 0/13 | 0/11 | 0/12 | 1/13 | 0/11 |
| ContusionInjury, poisoning and procedural complications | 0/4 | 0/2 | 0/281 | 1/281 | 0/62 | 2/27 | 0/11 | 0/11 | 0/11 | 1/12 | 0/13 | 0/12 | 0/13 | 0/11 | 2/12 | 0/13 | 0/11 |
| ConstipationGastrointestinal disorders | 0/4 | 0/2 | 0/281 | 0/281 | 1/62 | 0/27 | 0/11 | 0/11 | 0/11 | 0/12 | 0/13 | 1/12 | 1/13 | 0/11 | 2/12 | 1/13 | 0/11 |
| DizzinessNervous system disorders | 0/4 | 0/2 | 0/281 | 0/281 | 0/62 | 0/27 | 0/11 | 0/11 | 0/11 | 0/12 | 0/13 | 2/12 | 1/13 | 0/11 | 0/12 | 0/13 | 0/11 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 0/2 | 5/281 | 4/281 | 1/62 | 1/27 | 0/11 | 0/11 | 0/11 | 0/12 | 0/13 | 0/12 | 0/13 | 0/11 | 0/12 | 0/13 | 1/11 |
One participant was withdrawn prior to washout period. 34 participants did not complete washout phase. 111 participants did not qualify to continue in the study after completing the Washout Phase. 6 participants were withdrawn during run-in phase and 3 participants were withdrawn during treatment phase.
| Age, Continuous(Years) | Part A | Part B | Total |
|---|---|---|---|
| Mean | 49.2 ± 5.34 | — | 49.2 ± 5.34 |
| Age, Continuous(Years) | Part A | Part B | Total |
|---|---|---|---|
| Mean | — | 57.7 ± 9.97 | 57.7 ± 9.97 |
| Sex: Female, Male(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Female | 0 | 152 | 152 |
| Male | 6 | 129 | 135 |
| Race/Ethnicity, Customized(Participants) | Part A | Part B | Total |
|---|---|---|---|
| African American/African Heritage | 1 | 32 | 33 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian - Central/South Asian Heritage | 0 | 2 | 2 |
| Asian - Japanese Heritage | 0 | 2 | 2 |
| Asian - South East Asian Heritage | 0 | 1 | 1 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White - Arabic/North African Heritage | 0 | 7 | 7 |
| White - White/Caucasian/European Heritage | 5 | 230 | 235 |
| White - Mixed Race | 0 | 1 | 1 |
| Mixed Race | 0 | 3 | 3 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Sep 2010 to primary completion in Jun 2011, 9 months.
Results were first posted in Nov 2017, 6 years 4 months after primary completion. A results delay was requested in Apr 2015.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Gsk-1292263